0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV-331.03%PremiumJul 19, 2024Expiry Date5.76Intrinsic Value100Multiplier-4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
TFF Pharmaceuticals Stock Discussion
TFF Pharmaceuticals, Cleveland Clinic Partner To Advance Multiple Multivalent Universal Influenza Vaccines To Protect Against Seasonal, Pandemic Viruses Into Preclinical Testing
NEWS
TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection
TFF Pharmaceuticals announced an update on its Phase 2 trial of Tacrolimus Inhalation Powder (TFF TAC) for preventing lung transplant rejection. The trial has accelerated patient enrollment with 10 patients currently enrolled. All 6 patients who completed the 12-week treatment have opted to continue to the safety extension...
NEWS
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
$Taysha Gene Therapies(TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US)$ 14% Clinical programs update
$Jaguar Health(JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US)$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US)$ 0...
No comment yet